Artículos de revistas sobre el tema "BOCEPREVIR RESISTANCE"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 40 mejores artículos de revistas para su investigación sobre el tema "BOCEPREVIR RESISTANCE".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Flint, Mike, Stanley Mullen, Anne M. Deatly, Wei Chen, Lynn Z. Miller, Robert Ralston, Colin Broom, Emilio A. Emini y Anita Y. M. Howe. "Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)". Antimicrobial Agents and Chemotherapy 53, n.º 2 (20 de octubre de 2008): 401–11. http://dx.doi.org/10.1128/aac.01081-08.
Texto completoAndonov, Anton, Kamran Kadkhoda, Carla Osiowy y Kelly Kaita. "Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba". Canadian Journal of Gastroenterology 27, n.º 7 (2013): 414–16. http://dx.doi.org/10.1155/2013/273856.
Texto completoBarnard, Richard J. O., John A. Howe, Robert A. Ogert, Stefan Zeuzem, Fred Poordad, Stuart C. Gordon, Robert Ralston et al. "Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies". Virology 444, n.º 1-2 (septiembre de 2013): 329–36. http://dx.doi.org/10.1016/j.virol.2013.06.029.
Texto completoWelsch, Christoph, Sabine Schweizer, Tetsuro Shimakami, Francisco S. Domingues, Seungtaek Kim, Stanley M. Lemon y Iris Antes. "Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease". Antimicrobial Agents and Chemotherapy 56, n.º 4 (17 de enero de 2012): 1907–15. http://dx.doi.org/10.1128/aac.05184-11.
Texto completoSerre, Stéphanie B. N., Sanne B. Jensen, Lubna Ghanem, Daryl G. Humes, Santseharay Ramirez, Yi-Ping Li, Henrik Krarup, Jens Bukh y Judith M. Gottwein. "Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants:In VitroSelection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle". Antimicrobial Agents and Chemotherapy 60, n.º 6 (28 de marzo de 2016): 3563–78. http://dx.doi.org/10.1128/aac.02929-15.
Texto completoTong, X., A. Arasappan, F. Bennett, R. Chase, B. Feld, Z. Guo, A. Hart et al. "Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease". Antimicrobial Agents and Chemotherapy 54, n.º 6 (2 de marzo de 2010): 2365–70. http://dx.doi.org/10.1128/aac.00135-10.
Texto completoJensen, Sanne B., Stéphanie B. N. Serre, Daryl G. Humes, Santseharay Ramirez, Yi-Ping Li, Jens Bukh y Judith M. Gottwein. "Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance". Antimicrobial Agents and Chemotherapy 59, n.º 12 (21 de septiembre de 2015): 7426–36. http://dx.doi.org/10.1128/aac.01953-15.
Texto completoNagpal, Neha, Sukriti Goyal, Divya Wahi, Ritu Jain, Salma Jamal, Aditi Singh, Preeti Rana y Abhinav Grover. "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease". Gene 570, n.º 1 (octubre de 2015): 115–21. http://dx.doi.org/10.1016/j.gene.2015.06.008.
Texto completoSusser, Simone, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes et al. "Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients". Hepatology 50, n.º 6 (4 de agosto de 2009): 1709–18. http://dx.doi.org/10.1002/hep.23192.
Texto completoBrass, Clifford A., Richard J. Barnard, John A. Howe, Robert A. Ogert, Robert Ralston, Navdeep Boparai, Margaret Burroughs, Vilma Sniukiene, Patricia Mendez y Janice K. Albrecht. "Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1A/1b When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin". Gastroenterology 140, n.º 5 (mayo de 2011): S—942—S—943. http://dx.doi.org/10.1016/s0016-5085(11)63909-7.
Texto completoBrass, C., R. J. O. Barnard, J. A. Howe, R. A. Ogert, R. Ralston, N. Boparai, M. Burroughs, V. Sniukiene, P. Mendez y J. Albrecht. "1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN". Journal of Hepatology 54 (marzo de 2011): S471—S472. http://dx.doi.org/10.1016/s0168-8278(11)61196-3.
Texto completoStrahotin, Cristina Simona y Michael Babich. "Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy". Advances in Virology 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/267483.
Texto completoChae, Hee Bok, Seon Mee Park y Sei Jin Youn. "Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives". Scientific World Journal 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/704912.
Texto completoLópez-Labrador, F. Xavier, Andrés Moya y Fernando Gonzàlez-Candelas. "Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates". Antiviral Therapy 13, n.º 4 (mayo de 2008): 481–94. http://dx.doi.org/10.1177/135965350801300413.
Texto completoCuypers, Lize, Pieter Libin, Yoeri Schrooten, Kristof Theys, Velia Chiara Di Maio, Valeria Cento, Maja M. Lunar et al. "Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning". Infection, Genetics and Evolution 53 (septiembre de 2017): 15–23. http://dx.doi.org/10.1016/j.meegid.2017.05.007.
Texto completoSalam, Kazi Abdus y Nobuyoshi Akimitsu. "Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives". BioMed Research International 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/467869.
Texto completoMacartney, Malcolm J., Dianne Irish, Simon H. Bridge, Ana Garcia-Diaz, Clare L. Booth, Adele L. McCormick, Wendy Labbett et al. "Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure". Antiviral Research 105 (mayo de 2014): 112–17. http://dx.doi.org/10.1016/j.antiviral.2014.02.019.
Texto completoTornai, István. "A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben". Orvosi Hetilap 156, n.º 21 (mayo de 2015): 849–54. http://dx.doi.org/10.1556/650.2015.30180.
Texto completoSumma, Vincenzo, Steven W. Ludmerer, John A. McCauley, Christine Fandozzi, Christine Burlein, Giuliano Claudio, Paul J. Coleman et al. "MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants". Antimicrobial Agents and Chemotherapy 56, n.º 8 (21 de mayo de 2012): 4161–67. http://dx.doi.org/10.1128/aac.00324-12.
Texto completoBehmard, Esmaeil y Ebrahim Barzegari. "Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study". Journal of Biomolecular Structure and Dynamics 38, n.º 7 (31 de mayo de 2019): 1938–45. http://dx.doi.org/10.1080/07391102.2019.1621212.
Texto completoSchaefer, Daniel y Xinlai Cheng. "Recent Advances in Covalent Drug Discovery". Pharmaceuticals 16, n.º 5 (28 de abril de 2023): 663. http://dx.doi.org/10.3390/ph16050663.
Texto completoSusser, Simone, Johannes Vermehren, Nicole Forestier, Martin Walter Welker, Natalia Grigorian, Caterina Füller, Dany Perner, Stefan Zeuzem y Christoph Sarrazin. "Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir". Journal of Clinical Virology 52, n.º 4 (diciembre de 2011): 321–27. http://dx.doi.org/10.1016/j.jcv.2011.08.015.
Texto completoBlack, S., P. McMonagle, R. Chase, S. Curry, R. J. O. Barnard, D. J. Hazuda, A. Y. Howe, J. A. Howe y R. A. Ogert. "1198 HCV NS3/4A PROTEASE RESISTANCE-ASSOCIATED VARIANTS (RAVS) IDENTIFIED IN GENOTYPE 1A PATIENTS EXHIBIT DIFFERENCES IN PHENOTYPIC RESISTANCE TO BOCEPREVIR AND TELAPREVIR IN GENOTYPE 1A REPLICON CELLS". Journal of Hepatology 56 (abril de 2012): S475. http://dx.doi.org/10.1016/s0168-8278(12)61210-0.
Texto completoFonseca-Coronado, S., A. Escobar-Gutierrez, K. Ruiz-Tovar, M. Y. Cruz-Rivera, P. Rivera-Osorio, M. Vazquez-Pichardo, J. C. Carpio-Pedroza, J. A. Ruiz-Pacheco, F. Cazares y G. Vaughan. "Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals". Journal of Clinical Microbiology 50, n.º 2 (23 de noviembre de 2011): 281–87. http://dx.doi.org/10.1128/jcm.05842-11.
Texto completoCento, V., V. C. Di Maio, D. Di Paolo, F. De Luca, V. Micheli, M. Tontodonati, M. C. Bellocchi et al. "63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR". Journal of Hepatology 58 (abril de 2013): S29. http://dx.doi.org/10.1016/s0168-8278(13)60065-3.
Texto completoZeuzem, Stefan, Richard J. Barnard, John A. Howe, Robert A. Ogert, Robert Ralston, Navdeep Boparai, Clifford A. Brass et al. "Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin". Gastroenterology 140, n.º 5 (mayo de 2011): S—943. http://dx.doi.org/10.1016/s0016-5085(11)63911-5.
Texto completoLarrat, Sylvie, Sophie Vallet, Sandra David-Tchouda, Alban Caporossi, Jennifer Margier, Christophe Ramière, Caroline Scholtes et al. "Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin". Journal of Clinical Microbiology 53, n.º 7 (29 de abril de 2015): 2195–202. http://dx.doi.org/10.1128/jcm.03633-14.
Texto completoZeuzem, S., R. J. Barnard, J. A. Howe, R. A. Ogert, R. Ralston, N. Boparai, C. A. Brass et al. "9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN". Journal of Hepatology 54 (marzo de 2011): S4—S5. http://dx.doi.org/10.1016/s0168-8278(11)60011-1.
Texto completoCurry, Stephanie, Ping Qiu y Xiao Tong. "Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay". Journal of Virological Methods 153, n.º 2 (noviembre de 2008): 156–62. http://dx.doi.org/10.1016/j.jviromet.2008.07.020.
Texto completoOgert, Robert A., Patricia Mendez, Janice K. Albrecht, Clifford A. Brass, Jianmin Long, John A. Howe, Robert Ralston, Richard J. Barnard y Daria Hazuda. "Presence of Baseline Boceprevir (Boc) Resistance-Associated Variants (Ravs) Appears Not to Influence Treatment Outcomes in the Majority of Patients Following Boc/PR Treatment". Gastroenterology 140, n.º 5 (mayo de 2011): S—946. http://dx.doi.org/10.1016/s0016-5085(11)63921-8.
Texto completoGottwein, Judith M., Sanne B. Jensen, Stéphanie B. N. Serre, Lubna Ghanem, Troels K. H. Scheel, Tanja B. Jensen, Henrik Krarup, Nathalie Uzcategui, Lotte S. Mikkelsen y Jens Bukh. "Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor". Antimicrobial Agents and Chemotherapy 57, n.º 12 (23 de septiembre de 2013): 6034–49. http://dx.doi.org/10.1128/aac.01176-13.
Texto completoOgert, Robert A., John A. Howe, John M. Vierling, Paul Y. Kwo, Eric J. Lawitz, Jonathan McCone, Eugene R. Schiff et al. "Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial F". Antiviral Chemistry and Chemotherapy 18, n.º 3 (2013): 387–97. http://dx.doi.org/10.3851/imp2549.
Texto completoHowe, John A., Ping Qiu, Robert A. Ogert, Patricia Mendez, Clifford A. Brass, Janice K. Albrecht, Robert Ralston, Richard J. Barnard y Daria Hazuda. "Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2B)/Ribavirin in HCV (G1)-Infected Patients". Gastroenterology 140, n.º 5 (mayo de 2011): S—944. http://dx.doi.org/10.1016/s0016-5085(11)63914-0.
Texto completoYau, Alan Hoi Lun y Eric M. Yoshida. "Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review". Canadian Journal of Gastroenterology and Hepatology 28, n.º 8 (2014): 445–51. http://dx.doi.org/10.1155/2014/549624.
Texto completoHowe, J. A., P. Qiu, R. A. Ogert, P. Mendez, C. A. Brass, J. Albrecht, R. Ralston, R. J. O. Barnard y D. Hazuda. "433 FREQUENCIES OF RESISTANCE-ASSOCIATED AMINO ACID VARIANTS DETECTED BY 454-SEQUENCING DURING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTRON (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN HCV (GT1)-INFECTED PATIENTS". Journal of Hepatology 54 (marzo de 2011): S176. http://dx.doi.org/10.1016/s0168-8278(11)60435-2.
Texto completoDi Maio, V. C., D. Armenia, V. Cento, D. Di Paolo, M. Tontodonati, V. Micheli, M. C. Bellocchi et al. "Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?" Digestive and Liver Disease 46 (febrero de 2014): e47-e48. http://dx.doi.org/10.1016/j.dld.2014.01.105.
Texto completoKjellin, Midori, Terése Wesslén, Erik Löfblad, Johan Lennerstrand y Anders Lannergård. "The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort". Upsala Journal of Medical Sciences 123, n.º 1 (2 de enero de 2018): 50–56. http://dx.doi.org/10.1080/03009734.2018.1441928.
Texto completoMakara, Mihály, Gábor Horváth, Judit Gervain, Alajos Pár, Ferenc Szalay, László Telegdy, István Tornai, Eszter Újhelyi y Béla Hunyady. "Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis". Orvosi Hetilap 153, n.º 10 (marzo de 2012): 375–94. http://dx.doi.org/10.1556/oh.2012.29338.
Texto completoHowe, John A., Jianmin Long, Stuart Black, Robert Chase, Patricia McMonagle, Stephanie Curry, Seth Thompson, Mark J. DiNubile y Anita Y. M. Howe. "Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin". Open Forum Infectious Diseases 1, n.º 2 (2014). http://dx.doi.org/10.1093/ofid/ofu078.
Texto completo"P094: Naturally occuring cross - resistance mutation to boceprevir and telaprevir in a naive chronic hepatitis-C patient: Presentation of a case". Journal of Viral Hepatitis 22 (junio de 2015): 68. http://dx.doi.org/10.1111/jvh.89_12425.
Texto completo